Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure

The DEFEAT-HF Study

Douglas P. Zipes, Petr Neuzil, Heinz Theres, David Caraway, Douglas L. Mann, Clas Mannheimer, Peter Van Buren, Cecilia Linde, Bengt Linderoth, Fred Kueffer, Scott A. Sarazin, Michael J L DeJongste

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives: The primary objective of the study was a change in left ventricular end-systolic volume index (LVESVi) from baseline to 6 months of spinal cord stimulation (SCS) therapy in the treatment arm compared to the control arm as measured by echocardiography. Secondary objectives were changes in peak oxygen uptake and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between the treatment arm and control arm from baseline through 6 months. Background: Abnormal neurohormonal activation is often responsible for progression of heart failure (HF). Treatment has often included drug therapy to modulate the neurohormonal axis. The purpose of the DEFEAT-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical study was to evaluate whether direct modulation of the nervous system through SCS improved HF metrics, including heart size, biomarkers, functional capacity, and symptoms. Methods: The DEFEAT-HF study was a prospective, multicenter randomized (3:2), parallel, single-blind, controlled study to investigate whether SCS was a feasible therapy for the treatment of systolic HF for patients with New York Heart Association functional class III HF, left ventricular ejection fraction (LVEF) ≤35%, QRS duration

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalJACC: Heart Failure
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Systolic Heart Failure
Spinal Cord
Heart Failure
Spinal Cord Stimulation
Stroke Volume
Therapeutics
Single-Blind Method
Brain Natriuretic Peptide
Nervous System
Echocardiography
Biomarkers
Oxygen
Drug Therapy

Keywords

  • Clinical trial results
  • Heart failure
  • Randomized
  • Spinal cord stimulation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Zipes, D. P., Neuzil, P., Theres, H., Caraway, D., Mann, D. L., Mannheimer, C., ... DeJongste, M. J. L. (2016). Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. JACC: Heart Failure, 4(2), 129-136. https://doi.org/10.1016/j.jchf.2015.10.006

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure : The DEFEAT-HF Study. / Zipes, Douglas P.; Neuzil, Petr; Theres, Heinz; Caraway, David; Mann, Douglas L.; Mannheimer, Clas; Van Buren, Peter; Linde, Cecilia; Linderoth, Bengt; Kueffer, Fred; Sarazin, Scott A.; DeJongste, Michael J L.

In: JACC: Heart Failure, Vol. 4, No. 2, 01.02.2016, p. 129-136.

Research output: Contribution to journalArticle

Zipes, DP, Neuzil, P, Theres, H, Caraway, D, Mann, DL, Mannheimer, C, Van Buren, P, Linde, C, Linderoth, B, Kueffer, F, Sarazin, SA & DeJongste, MJL 2016, 'Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study', JACC: Heart Failure, vol. 4, no. 2, pp. 129-136. https://doi.org/10.1016/j.jchf.2015.10.006
Zipes, Douglas P. ; Neuzil, Petr ; Theres, Heinz ; Caraway, David ; Mann, Douglas L. ; Mannheimer, Clas ; Van Buren, Peter ; Linde, Cecilia ; Linderoth, Bengt ; Kueffer, Fred ; Sarazin, Scott A. ; DeJongste, Michael J L. / Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure : The DEFEAT-HF Study. In: JACC: Heart Failure. 2016 ; Vol. 4, No. 2. pp. 129-136.
@article{a6d74a5e39464369b1993431c77c6ebd,
title = "Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study",
abstract = "Objectives: The primary objective of the study was a change in left ventricular end-systolic volume index (LVESVi) from baseline to 6 months of spinal cord stimulation (SCS) therapy in the treatment arm compared to the control arm as measured by echocardiography. Secondary objectives were changes in peak oxygen uptake and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between the treatment arm and control arm from baseline through 6 months. Background: Abnormal neurohormonal activation is often responsible for progression of heart failure (HF). Treatment has often included drug therapy to modulate the neurohormonal axis. The purpose of the DEFEAT-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical study was to evaluate whether direct modulation of the nervous system through SCS improved HF metrics, including heart size, biomarkers, functional capacity, and symptoms. Methods: The DEFEAT-HF study was a prospective, multicenter randomized (3:2), parallel, single-blind, controlled study to investigate whether SCS was a feasible therapy for the treatment of systolic HF for patients with New York Heart Association functional class III HF, left ventricular ejection fraction (LVEF) ≤35{\%}, QRS duration",
keywords = "Clinical trial results, Heart failure, Randomized, Spinal cord stimulation",
author = "Zipes, {Douglas P.} and Petr Neuzil and Heinz Theres and David Caraway and Mann, {Douglas L.} and Clas Mannheimer and {Van Buren}, Peter and Cecilia Linde and Bengt Linderoth and Fred Kueffer and Sarazin, {Scott A.} and DeJongste, {Michael J L}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.jchf.2015.10.006",
language = "English (US)",
volume = "4",
pages = "129--136",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure

T2 - The DEFEAT-HF Study

AU - Zipes, Douglas P.

AU - Neuzil, Petr

AU - Theres, Heinz

AU - Caraway, David

AU - Mann, Douglas L.

AU - Mannheimer, Clas

AU - Van Buren, Peter

AU - Linde, Cecilia

AU - Linderoth, Bengt

AU - Kueffer, Fred

AU - Sarazin, Scott A.

AU - DeJongste, Michael J L

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objectives: The primary objective of the study was a change in left ventricular end-systolic volume index (LVESVi) from baseline to 6 months of spinal cord stimulation (SCS) therapy in the treatment arm compared to the control arm as measured by echocardiography. Secondary objectives were changes in peak oxygen uptake and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between the treatment arm and control arm from baseline through 6 months. Background: Abnormal neurohormonal activation is often responsible for progression of heart failure (HF). Treatment has often included drug therapy to modulate the neurohormonal axis. The purpose of the DEFEAT-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical study was to evaluate whether direct modulation of the nervous system through SCS improved HF metrics, including heart size, biomarkers, functional capacity, and symptoms. Methods: The DEFEAT-HF study was a prospective, multicenter randomized (3:2), parallel, single-blind, controlled study to investigate whether SCS was a feasible therapy for the treatment of systolic HF for patients with New York Heart Association functional class III HF, left ventricular ejection fraction (LVEF) ≤35%, QRS duration

AB - Objectives: The primary objective of the study was a change in left ventricular end-systolic volume index (LVESVi) from baseline to 6 months of spinal cord stimulation (SCS) therapy in the treatment arm compared to the control arm as measured by echocardiography. Secondary objectives were changes in peak oxygen uptake and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between the treatment arm and control arm from baseline through 6 months. Background: Abnormal neurohormonal activation is often responsible for progression of heart failure (HF). Treatment has often included drug therapy to modulate the neurohormonal axis. The purpose of the DEFEAT-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical study was to evaluate whether direct modulation of the nervous system through SCS improved HF metrics, including heart size, biomarkers, functional capacity, and symptoms. Methods: The DEFEAT-HF study was a prospective, multicenter randomized (3:2), parallel, single-blind, controlled study to investigate whether SCS was a feasible therapy for the treatment of systolic HF for patients with New York Heart Association functional class III HF, left ventricular ejection fraction (LVEF) ≤35%, QRS duration

KW - Clinical trial results

KW - Heart failure

KW - Randomized

KW - Spinal cord stimulation

UR - http://www.scopus.com/inward/record.url?scp=84959123613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959123613&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2015.10.006

DO - 10.1016/j.jchf.2015.10.006

M3 - Article

VL - 4

SP - 129

EP - 136

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 2

ER -